 |
Tranzyme Pharma to Present at the 26th Annual JPMorgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.
and SHERBROOKE, Québec (December 19, 2007) Tranzyme
Pharma, a leading biopharmaceutical company developing small
molecule drugs for the treatment of gastrointestinal (GI) and
metabolic diseases, announced today that Vipin K. Garg, Ph.D.,
President and CEO, will present at the upcoming 26th Annual
JPMorgan Healthcare Conference being held from January 7-10,
2008. Tranzyme’s presentation will take place on Monday, January
7, 2008 at 3:30 p.m. PST at the Westin St. Francis Hotel in San
Francisco, CA.
Dr. Garg will provide a corporate overview and an update on the
two ongoing Phase IIb clinical trials of Tranzyme’s lead
product, TZP-101, an intravenous ghrelin agonist being
investigated for the treatment of severe gastroparesis and
post-operative ileus. In July 2007, the FDA granted TZP-101
fast-track designation for severe gastroparesis.
|
|
|
